{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:57:47Z","timestamp":1774562267020,"version":"3.50.1"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nBackground Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Elevated serum concentrations of myeloperoxidase (MPO) are associated with an increased risk of developing CVD. The objective of this study was to evaluate serum MPO levels, as well as other laboratory parameters, in individuals with ESRD, with and without CVD, undergoing hemodialysis.<\/jats:p><jats:p>\nMethods 80 volunteers were admitted, divided into the following groups: control group (CON): 20 individuals without chronic kidney disease (CKD); ESRD group: 45 individuals with CKD stage V and ESRD\/CVD group: 15 individuals with CKD stage V and with CVD. The following biomarkers were evaluated: MPO, High sensitivity C-reactive protein (hs-CRP) and \u03b11-acid glycoprotein, following the manufacturer's guidelines in the package inserts. The data were processed through the statistical software SPSS 20.0\u00ae.<\/jats:p><jats:p>\nResults The level of MPO for the CON group was 84\u2009ng\/mL (73\u201387\u2009ng\/mL), for the ESRD group 77\u2009ng\/mL (11\u201389\u2009ng\/mL) and for the ESRD\/CVD group 21\u2009ng\/mL (8\u201347\u2009ng\/mL), with a significant statistical difference of the ESRD\/CVD group from the CON and ESRD groups (p&lt;0.001). For the parameters hs-CRP and \u03b11-acid glycoprotein a statistical difference between the ESRD and ESRD\/CVD groups from the CON group (p&lt;0.0001) was observed, but not between the ESRD and ESRD\/CVD groups.<\/jats:p><jats:p>\nConclusion  It is suggested that further studies should be performed to define the potential role of MPO as a cardiovascular risk marker for patients with ESRD on hemodialysis.<\/jats:p>","DOI":"10.1055\/a-0895-5138","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T23:11:58Z","timestamp":1556838718000},"page":"731-736","source":"Crossref","is-referenced-by-count":5,"title":["Serum Myeloperoxidase, C-reactive Protein and \u03b11-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease"],"prefix":"10.1055","volume":"128","author":[{"given":"Cristiane","family":"Rickli","sequence":"additional","affiliation":[{"name":"State University of Ponta Grossa \u2013 UEPG, Ponta Grossa-PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Cristyane Kalva","family":"Borato","sequence":"additional","affiliation":[{"name":"State University of Ponta Grossa \u2013 UEPG, Ponta Grossa-PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anderson Jos\u00e9 de Melo E","family":"Silva","sequence":"additional","affiliation":[{"name":"State University of Ponta Grossa \u2013 UEPG, Ponta Grossa-PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Fatima Menegat","family":"Schuinski","sequence":"additional","affiliation":[{"name":"State University of Ponta Grossa \u2013 UEPG, Ponta Grossa-PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Henrique Frigieri","family":"Vilela","sequence":"additional","affiliation":[{"name":"Braincare Technological Development and Innovation LTDA, S\u00e3o Carlos-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos Rebuglio","family":"Vellosa","sequence":"additional","affiliation":[{"name":"State University of Ponta Grossa \u2013 UEPG, Ponta Grossa-PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/S0101-28002010000100010","article-title":"Estudo epidemiol\u00f3gico da doen\u00e7a renal cr\u00f4nica terminal no oeste do Paran\u00e1: Uma experi\u00eancia de 878 casos atendidos em 25 anos","volume":"32","author":"LA B Peres","year":"2010","journal-title":"J Bras Nefrol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12902-015-0063-9","article-title":"Thyroid dysfunction and dyslipidemia in chronic kidney disease patients","volume":"15","author":"S Khatiwada","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease","volume":"325","author":"A J Collins","year":"2003","journal-title":"Am J Med Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"108","author":"M J Sarnak","year":"2003","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?","volume":"3","author":"P Stenvinkel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ncpneph0954","article-title":"Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease","volume":"4","author":"J Kendrick","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1681\/ASN.2004070539","article-title":"Chronic kidney disease awareness, prevalence, and trends among U.S. Adults, 1999 to 2000","volume":"16","author":"J Coresh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1097\/01.ASN.0000143744.72664.66","article-title":"Effect of an increase in C-reactive protein level during a hemodialysis session on mortality","volume":"15","author":"J C Korevaar","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"ref9","first-page":"84","article-title":"Immune disorders in hemodialysis patients","volume":"9","author":"M R Sharif","year":"2015","journal-title":"Iran J Kidney Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrneph.2011.2","article-title":"Monitoring of inflammation in patients on dialysis: Forewarned is forearmed","volume":"7","author":"C L Meuwese","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5301\/jn.5000169","article-title":"Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: A systematic review and meta-analysis","volume":"26","author":"W Zhang","year":"2013","journal-title":"J Nephrol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0272-6386(03)00407-4","article-title":"Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease","volume":"42","author":"V Menon","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1523-1755.2004.00736.x","article-title":"Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein","volume":"66","author":"M Busch","year":"2004","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2011.02.017","article-title":"Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - A cross-sectional study of predialysis, dialysis and kidney-transplantation patients","volume":"216","author":"A Recio-Mayoral","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/2277-9175.200788","article-title":"The role of inflammatory processes in occurrence of left ventricular failure in patients with chronic kidney disease","volume":"6","author":"H Shemirani","year":"2017","journal-title":"Adv Biomed Res"},{"key":"ref16","first-page":"233","article-title":"Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats","volume":"101","author":"T Kamori","year":"1998","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biochi.2012.09.005","article-title":"Fibrillation properties of human \u03b11-acid glycoprotein","volume":"95","author":"A Scir\u00e8","year":"2013","journal-title":"Biochimie"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12170-009-0022-y","article-title":"Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?","volume":"3","author":"B J Arsenault","year":"2009","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1194\/jlr.R800086-JLR200","article-title":"Myeloperoxidase, modified lipoproteins, and atherogenesis","volume":"50","author":"S J Nicholls","year":"2008","journal-title":"J Lipid Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12291-010-0075-1","article-title":"Myeloperoxidase in chronic kidney disease","volume":"26","author":"A Madhusudhana Rao","year":"2011","journal-title":"Indian J Clin Biochem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/CH-2009-1237","article-title":"Elastase, myeloperoxidase, nitric oxide metabolites and oxidative status in subjects with clinical stable chronic renal failure on conservative treatment","volume":"43","author":"G Caimi","year":"2009","journal-title":"Clin Hemorheol Microcirc"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.ajkd.2010.05.008","article-title":"Prognostic value of plasma Myeloperoxidase in ESRD patients","volume":"56","author":"AY M Wang","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2006.03.047","article-title":"Serum Myeloperoxidase and Mortality in Maintenance Hemodialysis Patients","volume":"48","author":"K Kalantar-Zadeh","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000477766","article-title":"Myeloperoxidase levels and its product 3-chlorotyrosine predict chronic kidney disease severity and associated coronary artery disease","volume":"46","author":"F Afshinnia","year":"2017","journal-title":"Am J Nephrol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/ndt\/gfh764","article-title":"Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes","volume":"20","author":"C C Wu","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/jama.286.17.2136","article-title":"Association between myeloperoxidase levels and risk of coronary artery disease","volume":"286","author":"R Zhang","year":"2001","journal-title":"Jama"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000090690.67322.51","article-title":"Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes","volume":"108","author":"S Baldus","year":"2003","journal-title":"Circulation."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2010.08.015","article-title":"Diagnostic value of MPO plasma levels in patients admitted for suspected myocardial infarction","volume":"153","author":"V Rudolph","year":"2011","journal-title":"Int J Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/2277-9175.183663","article-title":"Association between serum myeloperoxidase levels and coronary artery disease in patients without diabetes, hypertension, obesity, and hyperlipidemia","volume":"5","author":"Z Hasanpour","year":"2016","journal-title":"Adv Biomed Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cca.2008.04.001","article-title":"Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease","volume":"394","author":"L Kubala","year":"2008","journal-title":"Clin Chim Acta"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000368468","article-title":"Mortality prediction using modern peptide biomarkers in hemodialysis patients - A comparative analysis","volume":"39","author":"F Artunc","year":"2014","journal-title":"Kidney Blood Press Res"},{"key":"ref32","first-page":"BC01","article-title":"Unusual dyslipidemia in patients with chronic kidney diseases","volume":"11","author":"R R Phukan","year":"2017","journal-title":"J Clin Diagnostic Res"},{"key":"ref33","first-page":"839","article-title":"Alkaline phosphatase, ipth and bone turnover markers in chinese advanced chronic kidney disease patients","volume":"61","author":"Y Liu","year":"2015","journal-title":"Clin Lab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000106","article-title":"Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients","volume":"93","author":"J F Chang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","article-title":"New treatment approaches for the anemia of CKD","volume":"67","author":"M Bonomini","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.krcp.2014.11.003","article-title":"Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients","volume":"34","author":"M Y Jung","year":"2015","journal-title":"Kidney Res Clin Pract"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients with heart failure","volume":"113","author":"H L Hillege","year":"2006","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin","volume":"34","author":"A Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5935\/0101-2800.20150054","article-title":"Left ventricular mass behaviour in hemodialysis patients during 17 years","volume":"37","author":"L G Cavalcante","year":"2015","journal-title":"J Bras Nefrol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000441583","article-title":"Cardiorenal syndrome in end-stage kidney disease","volume":"40","author":"K Tsuruya","year":"2015","journal-title":"Blood Purif"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0895-5138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T23:36:33Z","timestamp":1603928193000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0895-5138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,28]]},"published-print":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0895-5138","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]}}}